BioNexus Gene Lab (BGLC) CEO Tan Lee Su-Leng Receives Award

What Happened
Tan Lee Su-Leng, CEO of BioNexus Gene Lab Corp., was granted a fully vested other stock-based award of 338,709 shares on August 13, 2026. The award was granted under the company's 2025 Equity Incentive Plan for completed services, for no cash consideration, and was valued for plan purposes at $1.55 per share (Nasdaq close on Aug 12, 2026), or roughly $524,999 in total. This was an award/compensation grant (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: August 13, 2026 (reported on Form 4 filed Aug 14, 2026) — filing appears timely.
• Shares granted: 338,709; per‑share plan valuation: $1.55; total plan value ≈ $524,998.95.
• Consideration: No cash paid; award given for completed services.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Award is fully vested at grant and issued under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan.

Context
This is a compensation award rather than a purchase (which might be viewed as a direct bullish signal) or a sale. Because the award is fully vested, the CEO generally has the ability to sell these shares subject to company policies and insider‑trading windows; the filing does not indicate any immediate sale or tax withholding. As always, awards reflect compensation decisions and should be interpreted differently from open‑market insider purchases or sales.